These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12854891)

  • 1. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
    Eleutherakis-Papaiakovou V; Karali M; Kokkonouzis I; Tiliakos I; Dimopoulos MA
    Leuk Lymphoma; 2003 Jun; 44(6):937-48. PubMed ID: 12854891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis in patients with hematologic malignancies].
    Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
    Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in multiple myeloma.
    Rajkumar SV; Kyle RA
    Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of antiangiogenic effect in multiple myeloma treatment.
    Barchnicka A; Olejniczak-Nowakowska M; Krupa-Kotara K; Grosicki S
    Adv Clin Exp Med; 2018 Feb; 27(2):291-297. PubMed ID: 29521075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiangiogenic therapy in hematologic malignancies.
    Moehler TM; Hillengass J; Goldschmidt H; Ho AD
    Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
    Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
    Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy in multiple myeloma.
    Tosi P; Tura S
    Acta Haematol; 2001; 106(4):208-13. PubMed ID: 11815718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic switch in multiple myeloma.
    Giuliani N; Colla S; Rizzoli V
    Hematology; 2004; 9(5-6):377-81. PubMed ID: 15763977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow angiogenesis in multiple myeloma: effect of therapy.
    Kumar S; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
    Br J Haematol; 2002 Dec; 119(3):665-71. PubMed ID: 12437642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiogenesis and endothelial cells in blood neoplasms].
    Usnarska-Zubkiewicz L; Poreba M; Kuliczkowski K
    Przegl Lek; 2006; 63(3):146-50. PubMed ID: 16969900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of thalidomide in the treatment of cancer.
    Rajkumar SV
    Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization.
    Schreiber S; Ackermann J; Obermair A; Kaufmann H; Urbauer E; Aletaha K; Gisslinger H; Chott A; Huber H; Drach J
    Br J Haematol; 2000 Sep; 110(3):605-9. PubMed ID: 10997971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis in hematologic malignancies.
    Moehler TM; Neben K; Ho AD; Goldschmidt H
    Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
    Vacca A; Ribatti D; Roncali L; Dammacco F
    Leuk Lymphoma; 1995 Dec; 20(1-2):27-38. PubMed ID: 8750620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.